Corcept Therapeutics (CORT) Stock Overview
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CORT Community Fair Values
Create NarrativeSee what 117 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Corcept Therapeutics Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$35.70 |
| 52 Week High | US$117.33 |
| 52 Week Low | US$28.66 |
| Beta | 0.26 |
| 1 Month Change | -10.46% |
| 3 Month Change | -55.25% |
| 1 Year Change | -41.07% |
| 3 Year Change | 85.94% |
| 5 Year Change | 45.42% |
| Change since IPO | 191.91% |
Recent News & Updates
Recent updates
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug
Jan 04The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%
Jan 01
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable
Oct 07Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 35% Price Jump
Apr 08We Think Corcept Therapeutics' (NASDAQ:CORT) Solid Earnings Are Understated
Mar 05Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 39% Price Jump
Jan 31Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors
Jan 01Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Just Right With A 25% Price Jump
Dec 04Shareholder Returns
| CORT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.5% | 2.8% | -0.6% |
| 1Y | -41.1% | 25.1% | 15.5% |
Return vs Industry: CORT underperformed the US Pharmaceuticals industry which returned 25.1% over the past year.
Return vs Market: CORT underperformed the US Market which returned 15.5% over the past year.
Price Volatility
| CORT volatility | |
|---|---|
| CORT Average Weekly Movement | 17.8% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CORT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CORT's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 730 | Joseph Belanoff | www.corcept.com |
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig’s disease.
Corcept Therapeutics Incorporated Fundamentals Summary
| CORT fundamental statistics | |
|---|---|
| Market cap | US$3.80b |
| Earnings (TTM) | US$98.17m |
| Revenue (TTM) | US$761.41m |
Is CORT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CORT income statement (TTM) | |
|---|---|
| Revenue | US$761.41m |
| Cost of Revenue | US$12.98m |
| Gross Profit | US$748.43m |
| Other Expenses | US$650.26m |
| Earnings | US$98.17m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.92 |
| Gross Margin | 98.30% |
| Net Profit Margin | 12.89% |
| Debt/Equity Ratio | 0% |
How did CORT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/01 10:28 |
| End of Day Share Price | 2026/02/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Corcept Therapeutics Incorporated is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Debjit Chattopadhyay | Brean Capital Historical (Janney Montgomery) |
| David Buck | B. Riley Securities, Inc. |